Product name: Erlotinib Hydrochloride
CAS:183319-69-0
Molecular formula:C22H23N3O4·HCl
Molecular weight:429.9
Product description:Erlotinib monotherapy applicable to at least one of previously treated locally advanced or metastatic chemotherapy after the failure of non-small cell lung cancer (NSCLC). More than two centers, Ⅲ trial randomized, placebo-controlled, showed that erlotinib combined with platinum-containing chemotherapy (carboplatin + paclitaxel; or gemcitabine + cisplatin) as locally advanced or metastatic NSCLC patients with first-line treatment, relative to platinum-containing chemotherapy alone did not increase the clinical benefit and is not recommended first-line treatment for the above conditions.